Difference between revisions of "Part:BBa K5384001:Design"

(→‎References)
 
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
Vglycin has excellent hypoglycemic effect.
+
We used this part in three construct (BBa_K5384007, BBa_K5384008, BBa_K5384009) designed for the purpose of introducing Vglycin’s biosynthetic pathway into Pichia pastoris.  
  
  
Line 16: Line 16:
  
 
===References===
 
===References===
−
1.Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058.
+
[1] Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058.
−
2.Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.
+
 
 +
[2] Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.

Latest revision as of 07:33, 1 October 2024


Vglycin (Vg)


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

We used this part in three construct (BBa_K5384007, BBa_K5384008, BBa_K5384009) designed for the purpose of introducing Vglycin’s biosynthetic pathway into Pichia pastoris.


Source

vglycin is a 37-amino-acid peptide derived from legumes.

References

[1] Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. BMC Med. 15(1), 45.Charlton, M. (2004). Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin gastroenterol hepatol. 2, 1048–1058.

[2] Vuppalanchi, R., & Chalasani, N. (2009). Nonalcoholic fatty liver disease and nonalco holic steatohepatitis: Selected practical issues in their evaluation and management.Hepatology, 49, 306–317.